Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 May 31;13:1744806917709371. doi: 10.1177/1744806917709371

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 7. — Retigabine inhibits bradykinin-evoked afferent activation in human colon. (a) Representative recording showing human mesenteric afferent excitation to bradykinin (1 µM); an effect that is inhibited in the presence of K_V7 channel opener retigabine. Upon washout of retigabine, bradykinin-evoked afferent excitation is recovered. Top, example rate histogram; middle, raw neurogram traces and bottom, expanded traces showing human action potential firing during the application of bradykinin under different conditions. (b) Average response to bradykinin before, during and after the addition of retigabine (N = 6). *P < 0.05 versus control, one-way ANOVA with Bonferroni post hoc.